Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026
New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS® (zongertinib tablets) as an initial treatment option in HER2 (ERBB2)-mutant advanced non-small cell…
